FDA: Medtronic brain stimulator missed study goal
Go Deeper.
Create an account or log in to save stories.
Like this?
Thanks for liking this story! We have added it to a list of your favorite stories.
The Food and Drug Administration says a Medtronic nerve stimulating implant failed to significantly reduce seizures in epilepsy patients.
Medtronic Inc. has asked the FDA to approve its Deep Brain Stimulation implant for epilepsy, a neurological disease that causes seizures.
The device is already used to treat other movement disorders, including Parkinson's Disease.
In documents posted online, the FDA says Medtronic's device failed to meet its primary study goal, which was a reduction in seizures after three months in patients with the device compared to those without it.
After Medtronic completed the study, the FDA says the company re-analyzed the data to show a significant reduction.
The FDA will ask a panel to weigh those results this Friday.
(Copyright 2010 by The Associated Press. All Rights Reserved.)
Turn Up Your Support
MPR News helps you turn down the noise and build shared understanding. Turn up your support for this public resource and keep trusted journalism accessible to all.